These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33526378)

  • 21. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.
    Waki F; Ando M; Takashima A; Yonemori K; Nokihara H; Miyake M; Tateishi U; Tsuta K; Shimada Y; Fujiwara Y; Tamura T
    J Neurooncol; 2009 Jun; 93(2):205-12. PubMed ID: 19043775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
    Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
    Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged survival of patients with breast cancer-related leptomeningeal metastases.
    Le Rhun E; Taillibert S; Zairi F; Pannier D; Boulanger T; Andre C; Cazin JL; Dubois F; Bonneterre J; Chamberlain MC
    Anticancer Res; 2013 May; 33(5):2057-63. PubMed ID: 23645756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer brain metastases: Molecular subtype, treatment and survival.
    Crozier JA; Cornell LF; Rawal B; Perez EA
    Breast Dis; 2016; 36(4):133-141. PubMed ID: 27802190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
    Epaillard N; Lusque A; Jacot W; Mailliez A; Bachelot T; Arnedos M; Le Du F; Brain E; Ferrero JM; Massard V; Desmoulins I; Mouret-Reynier MA; Levy C; Gonçalves A; Leheurteur M; Petit T; Filleron T; Bosquet L; Pistilli B; Frenel JS
    ESMO Open; 2024 May; 9(5):103447. PubMed ID: 38703431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].
    Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
    Bull Cancer; 2017 Apr; 104(4):332-343. PubMed ID: 28214007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
    Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
    Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study.
    Le Rhun E; Taillibert S; Zairi F; Devos P; Pierret MF; Dubois F; Assaker R; Buisset E; Bonneterre J; Baranzelli MC
    J Neurooncol; 2011 Nov; 105(2):309-15. PubMed ID: 21547396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.
    Cacho-Díaz B; Salmerón-Moreno K; Alvarez-Alvarez A; Mendoza-Olivas LG; Alvarado-Miranda A; Villarreal-Garza C; Reynoso-Noverón N; Chávez-MacGregor M; Meneses-García AA
    Cancer; 2020 Aug; 126(15):3456-3463. PubMed ID: 32453447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
    Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
    J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palliative shunt surgery for patients with leptomeningeal metastasis.
    Murakami Y; Ichikawa M; Bakhit M; Jinguji S; Sato T; Fujii M; Sakuma J; Saito K
    Clin Neurol Neurosurg; 2018 May; 168():175-178. PubMed ID: 29567579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of breast cancer subtypes in elderly patients.
    Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
    Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
    Kim YJ; Kim JS; Kim IA
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.